X0306 4 2022-08-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001650126 Choi Jung C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2022-08-01 4 M 0 6145 A 200054 D Common Stock 2022-08-01 4 F 0 2126 32.40 D 197928 D Common Stock 25000 I By Trust Restricted Stock Units 2022-08-01 4 M 0 3125 0.00 D Common Stock 3125 3125 D Restricted Stock Units 2022-08-01 4 M 0 3020 0.00 D Common Stock 3020 9060 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The number of shares of the Issuer's Common Stock beneficially owned by the Reporting Person includes 2,535 shares, which, as a result of an administrative error by no fault of the Reporting Person, were inadvertently omitted from the Table I, Column 5 share totals disclosed on Forms 4 filed on behalf of the Reporting Person from August 31, 2017 to the present. Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,145 shares of Common Stock underlying the Reporting Person's RSUs. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Title: Chief Business and Strategy Officer /s/ Miguel Carrillo, Attorney-in-Fact 2022-08-03